New drugs and vaccines for priority pathogens in antimicrobial resistance – 2019
This call for proposals provides funding for clinical trials to be conducted in sub-Saharan Africa which the aim to develop new or improved medicinal products (drugs and vaccines) or combinations thereof against pathogens on the WHO priority list that also fall within the scope of the EDCTP2 programme, specifically Campylobacter, Salmonella, Streptococcus pneumoniae, and Mycobacterium tuberculosis.
Isoniazid resistance: Resetting the score with boosted ethionamide
TASK Foundation NPC (TASK), Cape Town, South Africa, with partners in France and Spain Project coordinator: Prof. Andreas Diacon Starting date: 01 January 20121 Duration: 30 months EDCTP grant amount: EUR 2,704,719 Grant agreement: RIA2019AMR-2657
A novel pan-TB regimen targeting both host and microbe
The Aurum Institute NPC, Johannesburg, South Africa, with partners in Germany, Mozambique, the Netherlands, South Africa, Tanzania, and the United States of America Project coordinator: Dr Robert Wallis Starting date: 01 October 2020 Duration: 60 months EDCTP grant amount: EUR 8,140,565 Grant agreement: RIA2019AMR-2647
Pediatric phase I/II age de-escalation dose-finding study of a vaccine against invasive non-typhoidal salmonellosis in sub-Saharan Africa
Sclavo Vaccines Association (SVA), Siena, Italy, with partners in Germany, Ghana, Italy, and Switzerland Project coordinator: Dr Rino Rappuoli Starting date: 01 March 2021 Duration: 48 months EDCTP grant amount: EUR 5,698,964 Grant agreement: RIA2019AMR-2658